Loading stock…

Caris Life Sciences, Inc. (CAI) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Caris Life Sciences, Inc.

CAIMarket cap $7.76BPrice $27.5

Country🇺🇸United States

SectorHealthcare

IndustryBiotechnology

Profiles tumors at the molecular level, helping doctors match cancer patients with the treatments most likely to work. Its AI-driven database holds over 700 million clinical and genomic data points, making it one of the largest precision oncology datasets in existence.

In Bastion Portfolios?

52W Return-13%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+46%10

Revenue Forecast

Rev CAGR (1y)+27%9

Rev CAGR (3y)+20%9

Rev CAGR (5y)+15%9

Earnings Forecast

EPS Growth Y+10%5

EPS Growth Y+2+227%10

EPS Growth Y+3+56%9

Quality

Margins

EBIT Margin15%6

Net Income Margin11%6

Free Cash Flow Margin13%6

Debt

Net Debt/EBITDA-1.810

Efficiency

ROE20%8

ROA10%8

Earnings Stability22

GEAR+AVERAGE55

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)961

P/E Ratio (Forward 3y)391

P/BV13.11

EV Multiples

EV/EBITDA Fwd461

EV/EBIT Fwd961

Yield

Free Cash Flow Yield1.6%4

Dividend Yieldna–

Momentum

Short term

1 month return+10%10

3 month return+57%10

YTD return+2%5

Mid term

Price vs 52wHigh82%5

1 year return-13%3

Long term

3 year return-2%3

5 year return-2%3

Risk Shield

Price Risk

Beta2.21

Volatility68%2

Free Cash Flow

Free Cash Flow Margin13%6

Free Cash Flow Yield1.6%4

Quality

ROCE16%8

Earnings Stability22

Net Debt/EBITDA-1.810

02Growth

Is it actually growing, and how fast?

CAICaris Life Sciences

Revenue FY25$812M

GROWTH RATING↗

VERY STRONG93 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+46%10

Revenue, next 1Y+27%9

Revenue, next 3Y, CAGR+20%9

Revenue, next 5Y, CAGR+15%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+227%10

EPS growth, FY28E+56%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 93% of companies worldwide.

Revenue grew 46%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 20%/yr over the next 3 years, ahead of most of the market.9/10

The runway holds up: revenue is set to grow 15%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 56%/yr vs revenue 20%/yr), so margins should widen.

WATCH

Revenue grew 46%/yr over the last 3 years; forecasts see it cooling to 20%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE55 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+10%10

3-month return+57%10

YTD return+2%5

MID & LONG-TERM▾SCORE

% of 52-week high82%5

1-year return-13%3

3-year return-2%3

5-year return-2%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+10%) and over three months (+57%).

WATCH

It's down 13% over the past year, now 18% below its 52-week high. That is a touch behind the market.

Returns sit at the market level so far this year (+2%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-1.9% over three years and -1.9% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

A poor multi-year track record but a sharp recent rally. Momentum is turning up, yet the trend is young and unproven — it needs follow-through to confirm rather than fade. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Caris Life Sciences, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

CAICaris Life Sciences

Revenue FY25$812M

GROWTH RATING↗

VERY STRONG93 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+46%10

Revenue, next 1Y+27%9

Revenue, next 3Y, CAGR+20%9

Revenue, next 5Y, CAGR+15%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E0%5

EPS growth, FY27E+227%10

EPS growth, FY28E+56%9

GROWTH ASSESSMENT

STRENGTHS

It out-grows 93% of companies worldwide.

Revenue grew 46%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 20%/yr over the next 3 years, ahead of most of the market.9/10

The runway holds up: revenue is set to grow 15%/yr over five years.9/10

Earnings are set to grow faster than sales (EPS about 56%/yr vs revenue 20%/yr), so margins should widen.

WATCH

Revenue grew 46%/yr over the last 3 years; forecasts see it cooling to 20%/yr.

WEAKNESSES

None flagged.

BOTTOM LINE

Elite Compounder

A top-tier grower that is slowing. The one thing to watch: the pace is cooling.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE55 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+10%10

3-month return+57%10

YTD return+2%5

MID & LONG-TERM▾SCORE

% of 52-week high82%5

1-year return-13%3

3-year return-2%3

5-year return-2%3

MOMENTUM ASSESSMENT

STRENGTHS

Strong recent results. The stock is outperforming over the past month (+10%) and over three months (+57%).

WATCH

It's down 13% over the past year, now 18% below its 52-week high. That is a touch behind the market.

Returns sit at the market level so far this year (+2%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-1.9% over three years and -1.9% over five), behind 70% of the market.

BOTTOM LINE

Early Turnaround

04Value

Are you paying a fair price for it?

Stop guessing on Caris Life Sciences, Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community